Stockscreener 앱 받기
4.23
3.20%
-0.14
시간 외 거래:
29.72
25.49
+602.60%
전일 마감가:
$4.37
열려 있는:
$4.37
하루 거래량:
561.77K
Relative Volume:
0.51
시가총액:
$310.20M
수익:
-
순이익/손실:
$-98.79M
주가수익비율:
-1.2936
EPS:
-3.27
순현금흐름:
$-51.66M
1주 성능:
-4.94%
1개월 성능:
-0.24%
6개월 성능:
+571.43%
1년 성능:
+799.81%
1일 변동 폭
$3.98
$4.48
1주일 범위
$3.98
$4.9899
52주 변동 폭
$0.2404
$5.12
Relmada Therapeutics Inc Stock (RLMD) Company Profile
명칭
Relmada Therapeutics Inc
전화
646 876 3459
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
3.24 | 4.27B | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
5.92 | 416.79M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.90 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
7.66 | 322.97M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
47.80 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-22 | 개시 | Jefferies | Buy |
| 2025-11-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-05 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-06-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-10-14 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2022-10-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 개시 | Mizuho | Buy |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-10-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-04 | 개시 | SunTrust | Buy |
| 2020-04-21 | 개시 | Goldman | Buy |
| 2020-01-27 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-16 | 개시 | Guggenheim | Buy |
모두보기
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Analyzing Citius Pharmaceuticals (NASDAQ:CTXR) and Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Corient Private Wealth LLC Invests $120,000 in Relmada Therapeutics, Inc. $RLMD - Defense World
Small Cap Biotech In 2025: Winning Pivots And Zombie Killers - Citeline News & Insights
Relmada’s BOOST Phase 3 Bladder Cancer Trial Sets Up a New Catalyst for RLMD Investors - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Update - Defense World
Jefferies Financial Group Begins Coverage on Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Stock Rating Upgraded by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage of Relmada Therapeutics (RLMD) with Buy Recommendation - Nasdaq
Relmada Therapeutics (RLMD) Initiates Coverage with Buy Rating | RLMD Stock News - GuruFocus
This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Treasury Yields: Is NEHC stock recession proof2025 Trading Recap & Weekly Stock Breakout Alerts - moha.gov.vn
Jefferies initiates Relmada Therapeutics stock with Buy rating on pipeline pivot - Investing.com Nigeria
Jefferies initiates Relmada Therapeutics stock with Buy rating on pipeline pivot By Investing.com - Investing.com South Africa
Jefferies Starts Relmada Therapeutics Inc (RLMD) at Buy - StreetInsider
Will Relmada Therapeutics Inc. stock benefit from infrastructure spendingJuly 2025 Movers & Weekly Momentum Stock Picks - Улправда
Inflation Data: Will Las Vegas Sands Corp stock outperform value peersPortfolio Return Summary & Real-Time Market Sentiment Reports - moha.gov.vn
Will Relmada Therapeutics Inc. (4E2) stock outperform energy sector in 2025Product Launch & Entry Point Confirmation Signals - Улправда
Is Relmada Therapeutics Inc. stock supported by strong cash flowsPortfolio Growth Summary & Entry Point Confirmation Alerts - Улправда
Why Relmada Therapeutics Inc. stock remains undervalued2025 Buyback Activity & Real-Time Buy Zone Alerts - Улправда
Momentum Shift: Why Relmada Therapeutics Inc. (4E2) stock benefits from AI revolution2025 Performance Recap & Low Risk Growth Stock Ideas - Улправда
Recap Report: Is Relmada Therapeutics Inc. stock supported by strong cash flowsBond Market & AI Enhanced Trading Alerts - Улправда
How supply chain issues affect Relmada Therapeutics Inc. stockJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда
How Relmada Therapeutics Inc. (4E2) stock moves in volatile trading sessions2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - Улправда
Is Relmada Therapeutics Inc. stock supported by innovation pipeline2025 Market Trends & Reliable Intraday Trade Alerts - Улправда
Have you been able to find a good deal on Relmada Therapeutics Inc’s shares? - uspostnews.com
RelmadaA New Contender To Watch In Bladder Cancer Drug Development? - RTTNews
Maged Shenouda Increases Stake in Relmada Therapeutics Inc (RLMD) - GuruFocus
Relmada Therapeutics (NASDAQ:RLMD) CFO Buys $48,059.80 in Stock - MarketBeat
Relmada Therapeutics updates executive contracts and increases salaries By Investing.com - Investing.com Australia
Relmada Therapeutics Amends Executive Employment Agreements - TipRanks
Relmada Therapeutics updates executive contracts and increases salaries - Investing.com
What analysts say about Relmada Therapeutics Inc stockMarket Insider Reports & Exceptional Profit Growth Tips - earlytimes.in
Aug Drivers: Can Relmada Therapeutics Inc stock outperform in 2025 bull marketAnalyst Upgrade & Safe Entry Trade Reports - moha.gov.vn
Comparing BeOne Medicines (NASDAQ:ONC) & Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Taking on analysts’ expectations and winning: Relmada Therapeutics Inc (RLMD) - setenews.com
Relmada Therapeutics (RLMD) Price Target Increased by 900.00% to 10.20 - Nasdaq
Can Relmada Therapeutics Inc. stock hit analyst price targetsM&A Rumor & Technical Pattern Based Signals - Newser
Will Relmada Therapeutics Inc. (4E2) stock outperform value peersJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - Newser
Will Relmada Therapeutics Inc. stock deliver strong dividend growthGap Down & Risk Adjusted Buy and Sell Alerts - Newser
Relmada Therapeutics’ Earnings Call Highlights Clinical and Financial Success - MSN
Relmada’s bladder cancer therapy shows 92% complete response rate By Investing.com - Investing.com Nigeria
Relmada’s bladder cancer therapy shows 92% complete response rate - Investing.com India
Relmada Therapeutics Advances NDV-01 for Non-Muscle Invasive Bladder Cancer with Positive Phase 2 Follow-Up Data - Quiver Quantitative
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology - GlobeNewswire
A History of Outperforming Analyst Forecasts and Beating the Odds: Relmada Therapeutics Inc (RLMD) - setenews.com
Why Relmada Therapeutics Inc. (4E2) stock stays resilientRecession Risk & Trade Opportunity Analysis - Newser
Relmada Therapeutics Inc (RLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.03%
0.06%
자본화:
|
볼륨(24시간):